-
Hangzhou police cracked a case of illegally processed beef shutters
Time of Update: 2022-11-13
Recently, the Hangzhou Municipal Public Security Organ organized the "Loyalty No. 5" operation, and together with Hangzhou Municipal Market Supervision and other departments, carried out a centralized net collection of cases of production and sale of toxic and harmful food (illegally processed beef shutters) in Yuhang, Xiaoshan, and Deqing in Huzhou, arresting a total of 27 people involved in the case, destroying 7 gangs, destroying 7 illegal processing and storage dens, and 2 tons of finished internal organs.
-
Over 10%! Sales of 98 brands of drugs over 100 million soared
Time of Update: 2022-10-31
js?cdnversion='+~(-new Date()/36e5)]; According to the latest data from Intranet, the sales scale of terminal chemical drugs in public hospitals in key provinces and cities in the first half of 2022 exceeded 100 billion yuan, a slight decline from the same period last year.
-
The State Food and Drug Administration approved Pfizer's new crown treatment drug Nematicavir Tablets/Ritonavir Tablets Combination Package Import Registration
Time of Update: 2022-03-08
The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner .
-
At the beginning of the new year, multinational pharmaceutical companies have started the road of "buy, buy, buy
Time of Update: 2022-01-24
In order to increase the scale of the industry, reduce homogeneous competition, and expand the enterprise, pharmaceutical companies will continue to enrich the product pipeline and improve the research and development strength of innovative drugs .
-
Mengke Pharmaceutical is selected as the 2020 Shanghai High-tech Enterprise Cultivation List
Time of Update: 2021-10-21
"Being selected into the 2020 Shanghai High-tech Enterprise Storage Cultivation List marks that Mengke Pharmaceutical's scientific research and innovation capabilities have once again been recognized by the authority .
-
The FDA will hold an advisory committee meeting to discuss Merck and Ridgeback's oral COVID-19 treatment molnupiravir
Time of Update: 2021-10-19
On November 30, the advisory committee will hold a meeting to discuss the decision to support the use of molnupiravir to treat patients with mild to moderate COVID-19 .
-
Tianyao Pharmaceutical's adrenaline hydrochloride injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-17
In November 2019, Jinyao Pharmaceutical submitted a supplementary application for consistency evaluation to the Drug Evaluation Center of the National Medical Products Administration and was accepted .
-
After chronic hepatitis B has been treated with nucleoside analogues for a long time, the effect of switching to or adding interferon is evaluated
Time of Update: 2021-06-01
549) published a study in which Lim and others from Singapore conducted a randomized controlled trial on patients receiving long-term NA treatment to evaluate the interference of switching or adding polyethylene glycol Efficacy and safety of the treatment of CHB patients.
-
Osaicam posaconazole injection is about to pass the consistency evaluation
Time of Update: 2021-05-10
Recently, NMPA official website data shows that Osaikon’s posaconazole injection 3 types of imitation listing applications have entered the "under review" status, and it is expected to win the first domestic imitation + first review.
-
Greenlee Pharmaceuticals has teamed up with AstraZeneta to advance its cardiovascular business
Time of Update: 2021-03-05
the evening of January 15, Greenlee Pharmaceuticals, a Hong Kong-listed company, announced that it would grant AstraZene the right to promote the group's first-line lipid management drug, Lipid Kang capsules, at Chinese mainland.
-
Circulation enterprises change bureau 510,000 armed enterprises face a large number of elimination
Time of Update: 2021-03-04
"China's national medicine, medicine, China Resources, Kyushua to the four major circulation enterprises, accounting for less than 40% of the national circulation share, the concentration of the equipment industry is worse, but in Europe and the United States, Japan, the industry head circulation enterprises in the market share of more than 75%, or even as high as 95%." The above-mentioned person in charge said.
-
55 rare disease drugs into health insurance, price negotiations supporting the interpretation of the supporting documents: give medicine will become a trend
Time of Update: 2021-01-20
the 2020 National Health Care Drug Catalog negotiations, the annual cost of treatment for rare diseases that have not yet been on the list is very high.
-
Nine reference formulations were not considered, including Torasemi tablets
Time of Update: 2020-07-18
On June 30, CDE released the 30th batch of chemical generic reference preparations, including 171 reference formulations, revised 1 reference formulation, and 9 failed In January this year, the CDE
-
The accelerated arrival of the AI pharmaceutical era has helped pharmaceutical companies set off a wave of innovation
Time of Update: 2020-07-16
Pharmaceutical Network Market Analysis: The development of new drugs has always been a time-consuming and costly process , according to the Taft Center for Drug Development, a drug takes an average o
-
Overview of $20 billion asthma / COPD drug market
Time of Update: 2020-06-19
Asthma and chronic obstructive pulmonary disease (asthma / COPD) are two common chronic respiratory diseases Patients usually need long-term medication and their quality of life is greatly affected It
